AstraZeneca has become the latest member of the Worldwide Innovative Network (WIN) to assist in the research and development of new cancer treatments.
The British pharma company is the newest recruit of the unique global cancer network, joining a team of academics, industry members, payers and patient advocacy groups working towards making personalised cancer treatments a viable reality for patients.
The WIN Consortium, which now consists of 32 members across five continents, was initiated in 2010 with the combined leadership of Institut Gustave Roussy (France) and the University of Texas MD Anderson Cancer Centre (USA), and operates from Paris.
Also joining the consortium with AstraZeneca are the German Cancer Research Centre and the European Organisation for the Research and Treatment of Cancer, adding their expertise to the effort of achieving a significant improvement in survival rates and quality of life for all cancer sufferers over the next three years.
Dr Antoine Yver, head of oncology at AstraZeneca’s global medicines development unit, cited the company’s “rich heritage in oncology research and development” and said AstraZeneca would “achieve a lot by joining forces with others to progress the best science and accelerate development in the next generation of medicines.”
This collaboration follows swiftly on the company’s announcement of a partnership with Horizon Discovery to research new oncology treatments a few weeks ago.